SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001144204-19-004123
Filing Date
2019-01-31
Accepted
2019-01-31 16:59:41
Documents
6
Period of Report
2019-01-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K tv512185_6k.htm 6-K 13605
2 EXHIBIT 99.1 tv512185_ex99-1.htm EX-99.1 16994
3 EXHIBIT 99.2 tv512185_ex99-2.htm EX-99.2 9490
4 EXHIBIT 99.3 tv512185_ex99-3.htm EX-99.3 14052
5 GRAPHIC image_001.jpg GRAPHIC 7365
6 GRAPHIC image_002.jpg GRAPHIC 988
  Complete submission text file 0001144204-19-004123.txt   67060
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Bioblast Pharma Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 19556533
SIC: 2834 Pharmaceutical Preparations